GH effect on enzyme activity of 11betaHSD in abdominal obesity is dependent on treatment duration.

Abstract

OBJECTIVE:

In the past years the interaction of GH and 11beta hydroxysteroid dehydrogenase (11betaHSD) in the pathogenesis of central obesity has been suggested.

DESIGN:

We studied the effects of 9 months of GH treatment on 11betaHSD activity and its relationship with body composition and insulin sensitivity in 30 men with abdominal obesity, aged 48-66 years, in a randomised, double-blind, placebo-controlled trial.

METHODS:

Urinary steroid profile was used to estimate 11betaHSD type 1 and 2 (11betaHSD1 and 11betaHSD2) activities. Abdominal s.c. and visceral adipose tissues were measured using computed tomography. Glucose disposal rate (GDR) obtained during a euglycaemic-hyperinsulinaemic glucose clamp was used to assess insulin sensitivity.

RESULTS:

In the GH-treated group the 11betaHSD1 activity decreased transiently after 6 weeks (P < 0.01) whereas 11betaHSD2 increased after 9 months of treatment (P < 0.05). Between 6 weeks and 9 months, GDR increased and visceral fat mass decreased. Changes in 11betaHSD1 correlated with changes in visceral fat mass between baseline and 6 weeks. There were no significant correlations between 11betaHSD1 and 11betaHSD 2 and changes in GDR.

DISCUSSION:

The study demonstrates that short- and long-term GH treatment has different effects on 11betaHSD1 and 11betaHSD2 activity. Moreover, the data do not support that long-term metabolic effects of GH are mediated through its action on 11betaHSD.

• Authors: Helga A Sigurjónsdóttir, Josef Koranyi, Magnus Axelson, Bengt-Ake Bengtsson, Gudmundur Johannsson
• Journal: European journal of endocrinology (Eur J Endocrinol) Vol. 154 Issue 1 Pg. 69-74 (Jan 2006) ISSN: 0804-4643 [Print] England
• PMID: 16381993 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Human Growth Hormone
• 11-beta-Hydroxysteroid Dehydrogenase Type 1
• 11-beta-Hydroxysteroid Dehydrogenase Type 2
• 11-beta-Hydroxysteroid Dehydrogenases
• Hydrocortisone

Topics

• 11-beta-Hydroxysteroid Dehydrogenase Type 1 (blood)
• 11-beta-Hydroxysteroid Dehydrogenase Type 2 (blood)
• 11-beta-Hydroxysteroid Dehydrogenases (blood, drug effects)
• Abdominal Fat (drug effects)
• Human Growth Hormone (administration & dosage, therapeutic use)
• Humans
• Hydrocortisone (blood)
• Insulin Resistance (physiology)
• Male
• Middle Aged
• Obesity (drug therapy, enzymology)
• Time Factors